Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study.

Jan van Lunzen,Andrea Antinori,Calvin Cohen,José Ramón Arribas,David A. Wohl,Armin Rieger,Anita Rachlis,Mark Bloch,Sorana Segal-Maurer,Will Garner,Danielle Porter,Matthew Bosse,David Piontkowsky,Susan K. Chuck,Shampa De-Oertel

Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study.

2016

Jan van Lunzen
Andrea Antinori
Calvin Cohen
José Ramón Arribas
David A. Wohl
Armin Rieger
Anita Rachlis
Mark Bloch
Sorana Segal-Maurer
Will Garner
Danielle Porter
Matthew Bosse
David Piontkowsky
Susan K. Chuck
Shampa De-Oertel

Objectives:To compare efficacy, safety, tolerability, and patient-reported outcomes between two single-tablet regimens, rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) and efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF), in HIV-1-infected, treatment-naive ad

Keywords:

Rilpivirine
Efavirenz
Immunology
Physical therapy
Medicine
Tolerability
therapy naive
composite score
Emtricitabine
Internal medicine
Rash
Adverse effect

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations